Clinical trial data of Medtronic Arctic Front CryoAblation Catheter System for treating AF to be presented

Medtronic, Inc. (NYSE: MDT) announced today pivotal data for the Medtronic Arctic Front® CryoAblation Catheter System will be presented as a late breaking clinical trial at the 59^th Annual Scientific Session of the American College of Cardiology on Monday, March 15 at 8 a.m. ET. The STOP-AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial is evaluating the safety and efficacy of the Arctic Front CryoAblation Catheter System for paroxysmal atrial fibrillation (AF) patients. The system is approved for use in Europe, Australia and Hong Kong and is under investigational use in the United States.

Additionally, data from the Medtronic-sponsored CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) clinical trial also will be presented as a late breaker on Monday, March 15. The trial is assessing how the use of the Medtronic CareLink® Network to remotely monitor patients with Medtronic cardiac resynchronization therapy-defibrillators (CRT-Ds) and implantable cardioverter-defibrillators (ICDs) equipped with Conexus® Wireless Telemetry might effectively enable better patient care and reduce unnecessary healthcare costs.

About Medtronic, Inc.